---
title: "安徽丰原药业股份有限公司 (000153.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/000153.SZ.md"
symbol: "000153.SZ"
name: "安徽丰原药业股份有限公司"
industry: "制药"
---

# 安徽丰原药业股份有限公司 (000153.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.bbcayy.com](https://www.bbcayy.com) |

## Company Profile

公司是丰原集团医药板块的上市公司，是安徽省第一家医药类上市公司，集医药研发、生产、销售于一体，属高新技术企业。现有五十余条通过 GMP 认证的生产线，产品涉及生物制药、化学制药、中成药、中药饮片、原料药五大领域，涵盖解热镇痛、妇儿、神经系统、心血管系统、泌尿系统、营养类、抗生素类等 7 大类、10 余个剂型、300 多个品种，拥有多个一、二类新药品种和多项产品自主知识产权，连锁药房全省超 300 家。公司主要业务包括医药制造和商业流通。公司主要产品包括腹膜透析液系列、电解质系列、果糖系列、脂肪乳系列、载药脂肪乳系列、氨基酸系列、盐酸氨溴索葡萄、糖注射液、单硝酸异山梨酯、葡萄糖注射液、乳酸左氧氟...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 169 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.81% |  |
| Net Profit YoY | -30.65% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.45 |  |
| Dividend Ratio | 1.53% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.04B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.15B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.55% | C |
| Profit Margin | 2.74% | C |
| Gross Margin | 13.62% | D |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.81% | D |
| Net Profit YoY | -30.65% | D |
| Total Assets YoY | 6.52% | B |
| Net Assets YoY | 5.13% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 3644.77% | A |
| OCF YoY | -3.81% | D |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.86 | B |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 57.21% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 安徽丰原药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.55%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2.74%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "13.62%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.81%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-30.65%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.52%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.13%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "3644.77%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-3.81%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.86",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "57.21%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.74 | 64/222 | 26.74 | 22.00 | 18.09 |
| PB | 1.45 | 27/222 | 1.50 | 1.45 | 1.39 |
| PS (TTM) | 0.73 | 4/222 | 0.77 | 0.73 | 0.67 |
| Dividend Yield | 1.53% | 83/222 | 1.76% | 1.54% | 1.48% |

## References

- [Company Overview](https://longbridge.com/en/quote/000153.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/000153.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/000153.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
